3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
12
Neoplasm Metastasis
10
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
6
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neuroendocrine Tumors
3
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Sarcoma
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Interventions
Magnetic Resonance Spectroscopy
5
lutetium Lu 177 dotatate
4
Specimen Handling
4
Radiosurgery
3
gallium Ga 68 dotatate
2
Ga(III)-DOTATOC
2
Bevacizumab
2
regorafenib
1
pembrolizumab
1
olaparib
1
neratinib
1
capivasertib
1
cabozantinib
1
brigatinib
1
abemaciclib
1
X-Rays
1
Watchful Waiting
1
Tablets
1
Surveys and Questionnaires
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Protons
1
Proton Therapy
1
Photons
1
Observation
1
ONC206
1
Nivolumab
1
Mental Status and Dementia Tests
1
Lysine
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
olaparib
×
90 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled